Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5669 participants.

Also called NCT02924727

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,669 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02924727
  • EudraCT 2016-002154-20
Other papers using this trial's data
  • Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction The New England journal of medicine, 2021-11-11 DOI, PubMed 34758252 PubMed links an erratum for this paper. Erratum: PMID 34965357
  • Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI Journal of the American College of Cardiology, 2024-03-05 DOI, PubMed 38418004
  • Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy Circulation, 2022-10-04 DOI, PubMed 36082663, PMC9529950 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial Circulation. Heart failure, 2023-05 DOI, PubMed 37125529
  • Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials JAMA cardiology, 2024-10-01 DOI, PubMed 39110471, PMC11307160 Not in the PMC Open Access subset.
  • Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MI Journal of the American Heart Association, 2023-09-05 DOI, PubMed 37609931, PMC10547323 In the PMC Open Access subset under CC BY-NC-ND.
  • The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial Circulation, 2022-12-06 DOI, PubMed 36321459

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02924727. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-09 (actual); primary completion 2021-02-26 (actual). Results posted on 2023-06-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
Acronym
PARADISE-MI
Condition
Acute Myocardial Infarction
Intervention (Drug)
LCZ696 (sacubitril/valsartan)
Intervention (Drug)
Ramipril
Intervention (Drug)
Placebo of LCZ696
Intervention (Drug)
Placebo of ramipril
Intervention (Drug)
Valsartan
Intervention (Drug)
Placebo of valsartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02924727
Content hash
63b31eddc4448069065454e77a641115add412ccf7e2d8458bc7f7ab5586c824